News | July 04, 2025
Sigachi updates on fire accident at its Pashamylaram Facility, Telangana
The company has confirmed that the deceased are 39
The company has confirmed that the deceased are 39
ART-123 is a recombinant human thrombomodulin approved in Japan in 2008
The site, spanning approximately 25,000 square meters, is expected to commence operations by the end of 2025
Treatment with XPro was well-tolerated and safe, even in the high risk ApoE4+/+ patient group, and ARIA-E or ARIA-H was not observed in any patients
The iStent platform uses tiny surgical implants to lower eye pressure by restoring the eye’s natural fluid drainage system in patients with glaucoma
New findings reveal bemarituzumab plus chemotherapy significantly improves survival in advanced gastric cancer, offering hope for targeted treatment options
The approval in China is supported by a robust local clinical development program confirming the drug’s safety, tolerability, and efficacy profile
The company has been awarded a contract for the supply of essential pharmaceutical formulations to government health institutions across Rajasthan
Review will evaluate effectiveness in treating alcohol withdrawal syndrome and supporting abstinence, as well as measures to mitigate risk of abuse
The company's decision to withdraw the MAA was due to the timing of the availability of Chemistry Manufacturing and Controls
Subscribe To Our Newsletter & Stay Updated
